Investment Thesis
Cosmos Health exhibits severe fundamental deterioration with negative profitability across all levels (operating margin -11.6%, net margin -19.7%) while generating negative free cash flow of -3.9M despite modest 2% revenue growth. The company's liquidity crisis is evident with a current ratio of 0.99x, minimal cash reserves of $889K, and negative operating cash flow, creating immediate solvency concerns for a wholesale drug distributor requiring substantial working capital.
Strengths
- Modest revenue growth of 2.0% YoY demonstrates business persistence in challenging environment
- Moderate leverage with debt-to-equity ratio of 0.23x provides some balance sheet flexibility
- Gross margin of 12.8% is typical for wholesale pharmaceutical distribution sector
Risks
- Severe liquidity crisis: current ratio of 0.99x with only $889K cash and negative operating cash flow creates imminent refinancing/covenant risk
- Persistent unprofitability: negative operating income of -$5.3M and net loss of -$9.0M indicate structural operational problems, not temporary headwinds
- Negative free cash flow of -$3.9M with FCF margin of -8.6% demonstrates unsustainable business model that burns cash despite revenue generation
- Interest coverage ratio of -4.3x indicates inability to service debt from operations, forcing reliance on asset depletion or external financing
Key Metrics to Watch
- Quarterly operating cash flow trend and path to positive OCF
- Cash balance and burn rate relative to available liquidity facilities
- Gross margin stability and operating expense control initiatives
- Working capital management efficiency (accounts receivable and inventory turns)
Financial Metrics
Revenue
45.6M
Net Income
-9.0M
EPS (Diluted)
$-0.32
Free Cash Flow
-3.9M
Total Assets
69.5M
Cash
889.4K
Profitability Ratios
Gross Margin
12.8%
Operating Margin
-11.6%
Net Margin
-19.7%
ROE
-38.9%
ROA
-12.9%
FCF Margin
-8.6%
Balance Sheet & Liquidity
Current Ratio
0.99x
Quick Ratio
0.84x
Debt/Equity
0.23x
Debt/Assets
66.7%
Interest Coverage
-4.25x
Long-term Debt
5.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T20:24:13.188875 |
Data as of: 2025-09-30 |
Powered by Claude AI